SENORES — Senores Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- IN₹25.67bn
- IN₹28.82bn
- IN₹3.98bn
- 21
- 17
- 87
- 34
Annual income statement for Senores Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | — |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 142 | 353 | 2,145 | 3,983 |
| Cost of Revenue | ||||
| Gross Profit | 61.4 | 226 | 1,030 | 2,176 |
| Selling / General / Administrative Expenses | ||||
| Depreciation and Amortization | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 129 | 243 | 1,829 | 3,254 |
| Operating Profit | 12.5 | 111 | 316 | 729 |
| Gain / Loss on Sale of Assets | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | 11.4 | 124 | 249 | 706 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | 9.91 | 84.3 | 327 | 583 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Net Income | 9.91 | 84.3 | 315 | 586 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | 9.91 | 84.3 | 315 | 586 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | 0.298 | 2.57 | 9.46 | 16.1 |